{"name":"Renibus Therapeutics, Inc.","slug":"renibus-therapeutics-inc","ticker":"","exchange":"","domain":"renibus.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Low Dose RBT-1","genericName":"Low Dose RBT-1","slug":"low-dose-rbt-1","indication":"Hypertension","status":"phase_2"},{"name":"RBT-1","genericName":"RBT-1","slug":"rbt-1","indication":"Hypertension","status":"phase_3"}]}],"pipeline":[{"name":"Low Dose RBT-1","genericName":"Low Dose RBT-1","slug":"low-dose-rbt-1","phase":"phase_2","mechanism":"Low Dose RBT-1 is a renin-angiotensin system inhibitor.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"RBT-1","genericName":"RBT-1","slug":"rbt-1","phase":"phase_3","mechanism":"RBT-1 is a small molecule that targets the renin-angiotensin system to treat hypertension.","indications":["Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNWGcyeEpTdnluZ005SUhqNm1KWVJEaklQcTlFMU9oLTJLckJaTU1HYlJwVmFDdkV1a05zbUIxMVg0N3N3d3FreHFLalpYMmlXSlZzeWNiOWl6X1hZVU5wbzNZR1pvcnc1WTZBd1RPenR2WXZYY0xCN1NhNXBCdTRSVEZ6MThmN0lZcmNHNUpnYlRxLVY2aURia280YnV6UUV5U0w3YndMUnE2U1NUbTdwTTA3TXg2WXFrb3NEM1VMSE03a3N1NWNrN3hFVEZMVE96Sy1namtFeFFBUzBIVkEwVHZDRll6bWxXZkRyN2NteFNUTTVWcE94ZUM3eHJLUE5Nb3JmQW5WMDhHcHZjRTUzRXN4Mmp5czJXckdBeEdFdEJWMEE?oc=5","date":"2025-04-25","type":"pipeline","source":"PR Newswire","summary":"Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA) - PR Newswire","headline":"Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxNSWdzZUNSN2lFZmdDVDhUQ2NxV3JkRzA1REdWb0RTT3pXMFRQWTBoU3M4bkhzSW5oZXBRMFM2cnRtRHQ0NWZwSVROMHhLNnktRlRDSl8xR2tXbTY5T2Q5dkpPenBjZEdIVjhWX2JpY2FrM2MzWmw2UFhMbmw5UkhYVG52V0p2d0hWOUpsclhqQVVaN1BPSVJCRWxMNWZBMkNSc2laRk9vdUVUT2t6Ukh0ZXlrQkpEcEJWNW4tT1ppbHlUSDdzejY4QWg1V0ZVREJqNjB1SlJYZTlVYk53N0FKZmxybTd1VTdUNGkxdFROa1NrS1AzQmlqbnlQSGg2eGpKWFdQMGhyc241SlV6ZHp5V3R4YnVwOGduMUtiUVV5OGV6WmpsVE4wNUxGY3FBUV9QdHRGTHl5empMZ1hiT3VfUHlRVERyU1pIanU0czdGcXV3SzZzTGRVOQ?oc=5","date":"2025-04-24","type":"trial","source":"PR Newswire","summary":"Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal Phase 3 Clinical Trial of RBT-1 to Reduce the Risk of Post-Operative Complications After Cardiac Surgery - PR Newswire","headline":"Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal Phase 3 Clinical Trial of RBT-1 to Reduce ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNVTBDaENGRGxZSzY1ejRsa3F0Zk91TTZEelJDX1pBTHpEX2VTZXJZcUxDVjV3Q1R0QlZMOC1Kd3lnZml6VWZTRUk4aXprMWIxQVdCOHR3OGMzcndDaGJPTE1OWERhb3NzUWtOX2NCRmZheDE2OGItYlh5UWhIeFZ4OTB3RjlGQjNNZHV2czc4NlJDUW9jMnFwVDMxSmk4WGc4aXcyc3lFeFVhV3Uyd1VFdXBmMzd1T1ROYVdCMXVWWGcxLXVfa3c?oc=5","date":"2024-10-02","type":"pipeline","source":"dallasinnovates.com","summary":"BioNTX To Honor Renibus Therapeutics CEO with its 2024 Dennis K. Stone Award at iC³ Conference - dallasinnovates.com","headline":"BioNTX To Honor Renibus Therapeutics CEO with its 2024 Dennis K. Stone Award at iC³ Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZDNQR1E4OXphUzYzcUlSVUxOWDhDMnRQTUswdW9yWXpNWXJVTzdyUmc1azh5UmpVYXJoTUg2MUJ0bWtVODJOWk4xSGU5Z01RN3A5QUFYaHFoSTlxMFBqSkVOdldYUzRRZmFDMEdTcjNZQ2d0Sk9uLVRkVG8zOTBQSEFiMVZRWVkzeUJEcHVyY1ZJam12V1k5cVRrdkZhYnljTzk3ZW9wOXIxZw?oc=5","date":"2024-09-06","type":"pipeline","source":"dallasinnovates.com","summary":"Health Wildcatters Adds Nine Startups, Boosting Its Portfolio to 118 Companies - dallasinnovates.com","headline":"Health Wildcatters Adds Nine Startups, Boosting Its Portfolio to 118 Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNbEx6Q3hRRHpJSnlDRFBKekhpdjdnUkkyY0QyQTg1MDN0dkd6Q1dWRmcxWkt2c3pZYWpET3VBcnIxM0RBaHJvMkVFTmVaaWxuQ21kZkQ5VEtocFJJcVdGbDNwcDAtaW1BS2xIQVV3cU14dnNNNUROYW5UR05mQ2x1S2RNMXZEcUlSSGZ0S25iWlFVS1lHemZ5ZlJaUjc4NTlJNlE?oc=5","date":"2024-08-12","type":"pipeline","source":"Crain's Chicago Business","summary":"Walgreens-brand cold medicine contains cancer-causing benzene - Crain's Chicago Business","headline":"Walgreens-brand cold medicine contains cancer-causing benzene - Crain's Chicago Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQbkh5bnlMS2hONXh4aWp6aktLWkI0QW1uZVZOdnNZck1GWUJ1Qy03RGc0Mi00QWIzTDRuNkxmRXZEQm80cWFPYVJXMzhHRzEwNERSYkJuZHFiemw0OHdXRFVDbEZMZEdrdUJabWdDdlFoQktIRTlmZmNaaVk0WnptOEIwcE9NN0NEemlWa29UelVPYVVndy1wZE5oSTJYdXBUUWUzNXVQU044U2psVzJERU9PN0tPVkpvRTM3UmxjanZKR0Nnc25MQTVSRkxITlZaWlRXdXgxb1k0UkxPdHRSdDJlRFJoWEJPcHRJajVzU21fY3dJWnVkZmlEZ0dKdjJvN1VNQg?oc=5","date":"2024-03-22","type":"pipeline","source":"dallasinnovates.com","summary":"Leadership Transition at Renibus Therapeutics: Co-Founder Appointed as Sole CEO - dallasinnovates.com","headline":"Leadership Transition at Renibus Therapeutics: Co-Founder Appointed as Sole CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNR1hpT2gxamNHTVIwMWY2WEtWV1dMUzIxSWotb2FFak5yUHpaWVZHXzBpVFVJbkd5elpMWE9jWWxNUW4yVnBZLWg0WWFoMUk1S3dBVFFfMFJwMHZ3TGJsbUl1TVZMOHpzT01GRTQ2QmpxZExqQnVJeUJQYUp0U1pGM3d1N29vaTF4OHIxR2d3?oc=5","date":"2024-03-22","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech","headline":"Chutes & Ladders—Bayer undergoes leadership shake-up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMUlkbUo2d0Q0SHNwTXIzbmxqd1FDU2JHSWdVclN6ZUVOUVVsRjhJY0lvekItMGc3dV92cXV6dXFOX3NlX0pJcy0yV08ycVNVc19qcXUxOElyZVRJSEVGODBXV1JLMXE0SGhqcHlnRTRtOGcwN2V4UWstQXR6bWd3ZFB5Ml9BTXFwYlpGT0pVdG1fMktrNUhKTk96ei1FMHgzaXpGeGk0Ym8?oc=5","date":"2023-01-06","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—2 more C-suite members leave Galapagos island - Fierce Biotech","headline":"Chutes & Ladders—2 more C-suite members leave Galapagos island","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPWHA4am1MaW9MS3p2Y1JxQS1TRkV3VUF1bUJYM0FyM255Z2RaaUM5ZEptblJ6QlRFeWJWa1A0WU9GTXZqeDk0VXo5NnZJeWlXUTh6QkMyZXdUdzB0Q3NyWXVLb0x2REdPekdkaTJhSEUyV2VGNzRwMHVObzRMSjY2bDZSRGQtRzhSVzNHVWhPcGN4SHhmRmNQZERLZlhHRW1MYi1Nc3NLNVpRbHFkSVRRNDQ4MXEwSmdDRF9YU3VmeDBWVjdhVzVjTlFmMzVoNjZFRTFKaTNyUmVOajU2Y0xheFNxM0E2TXF3R2N4b0tZWVZ4UXhrd3ZJMDZscWR0Zkg1dWlR?oc=5","date":"2022-02-15","type":"pipeline","source":"globenewswire.com","summary":"Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding - globenewswire.com","headline":"Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOSlhIdnFFSlNJY1NqNURYT1Y2WXBEdWFMeEpsTm9VTHp4eTNSNnotVWpoQXlUNVQ5ZTJHNHRFUEl3Yll6UTFvMDlGOC1fMzE1S2lhUVJsbkpvRlc3T19OdHFfSUZOdzRpd0RrUWJDWUpFbFlrTWNlQk0tempfZzNhVkpDX2pyakxhTFBKUFdka0JtZFBGR1E?oc=5","date":"2019-09-26","type":"pipeline","source":"The Business Journals","summary":"Entrepreneur who sold past company for $2.7B raises funding for DFW startup - The Business Journals","headline":"Entrepreneur who sold past company for $2.7B raises funding for DFW startup","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}